Confident Investing Starts With TipRanks Premium

Go Ultimate 55% OFF

DE:1YI0 Stock Latest News

Company AnnouncementsPurple Biotech Reinstates Isaac Israel as Interim CEO in Leadership Reshuffle4w ago6K PPBT

Company AnnouncementsPurple Biotech Shareholders Approve All AGM Proposals, File Results with U.S. SEC1M ago6K PPBT
Company AnnouncementsPurple Biotech Gains New U.S. Patent Allowance for CAPTN-3 Cancer Immunotherapy Platform2M ago6K PPBT
The FlyPurple Biotech issued notice of allowance from USPTO2M agoPPBT
Company AnnouncementsPurple Biotech Unveils August 2026 Corporate Update on Tri-Specific Immuno-Oncology Platform2M ago6K PPBT

Purple Biotech price target lowered to $17 from $30 at H.C. Wainwright

The FlyPurple Biotech price target lowered to $17 from $30 at H.C. Wainwright2M agoPPBT

Company AnnouncementsPurple Biotech Posts Q2 2026 Results as IM1240 Preclinical Data Strengthen Immunotherapy Platform2M ago6K PPBT

Company AnnouncementsPurple Biotech Sets September 8, 2026 AGM to Reshape Board Roles and Compensation Policy3M ago6K PPBT

Company AnnouncementsPurple Biotech Updates Investors on CAPTN-3 Platform and Pipeline as IM1240 Nears 2027 Clinic Entry4M ago6K PPBT
The FlyPurple Biotech presents new IM1240 data at EACR4M agoPPBT
Company AnnouncementsPurple Biotech Unveils IM1240 Preclinical Data at EACR 2026, Validating CAPTN-3 Immunotherapy Platform4M ago6K PPBT
The FlyPurple Biotech files $200M mixed securities shelf5M agoPPBT

Purple Biotech Q1 2026 Results Highlight CAPTN-3 Pivot and IM1240 Preclinical Momentum

Company AnnouncementsPurple Biotech Q1 2026 Results Highlight CAPTN-3 Pivot and IM1240 Preclinical Momentum5M ago6K PPBT

Company AnnouncementsPurple Biotech Unveils Promising IM1240 Preclinical Data From CAPTN-3 Immunotherapy Platform6M ago6K PPBT

The FlyPurple Biotech reports IM1240 demonstrates potent anti-tumor activity6M agoPPBT

Company AnnouncementsPurple Biotech Forms Scientific Advisory Board to Drive CAPTN-3 Tri-Specific Antibody Platform6M ago6K PPBT
Company AnnouncementsPurple Biotech Taps Converge Bio’s AI to Turbocharge Tri-Specific Antibody Platform7M ago6K PPBT
The FlyPurple Biotech announces collaboration with Converge Bio7M agoPPBT
TipRanks NewswirePurple Biotech Is Building What Could Be the Next Generation of Cancer Immunotherapy (NASDAQ: PPBT)7M agoCODX PPBT

Patent Cliff Risk: How Expiring Protections Threaten Purple Biotech’s Future Exclusivity and Returns

Company AnnouncementsPatent Cliff Risk: How Expiring Protections Threaten Purple Biotech’s Future Exclusivity and Returns7M agoPPBT

Company AnnouncementsPurple Biotech Updates March 2026 Corporate Outlook and Pipeline Milestones7M ago6K PPBT

The FlyPurple Biotech regains compliance with Nasdaq7M agoPPBT